WindRose Health Investors, a New York-based healthcare private equity firm, announced it has completed the acquisition of SubjectWell. This patient access marketplace connects people with health conditions to care options. The terms of the deal were not disclosed.
Utilizing a multi-channel network and precision digital outreach, SubjectWell’s marketplace of tens of millions of motivated patients with known health conditions is growing by 300,000+ patients per month. This marketplace, built on SubjectWell’s tailored patient recruitment technology, enables SubjectWell to support global vaccine, chronic, rare disease, and oncology clinical studies for pharma, biotech, clinical research sites, clinical research organizations, and other healthcare clients.
WindRose worked with SubjectWell’s executive team to acquire the business and provide additional growth capital to advance the next expansion phase. With WindRose’s investment, SubjectWell will accelerate the development of existing and new solutions and utilize its marketplace of diverse and hard-to-access patients to service healthcare companies needing qualified patients for clinical trials or market-ready treatments. SubjectWell’s management team will continue leading the company and remain active shareholders.
McDermott Will & Emery LLP acted as WindRose’s legal advisor, and Silicon Legal Strategy acted as SubjectWell’s legal advisor.
KEY QUOTES:
“We are thrilled to be partnering with WindRose as SubjectWell looks ahead to this next growth chapter. WindRose selects companies whose operational excellence is a key building block, and their team is aligned with SubjectWell’s vision. Together, we can continue to enhance our proprietary technology, machine learning algorithms, medical records integration and in-house medical engagement center, all fundamental to ensuring that eligible patients – who are desperately needed by the healthcare industry – get access to the care they desire.”
- Fred Martin, CEO of SubjectWell
“Driving efficiency, speed, quality, and access within clinical trials has been a recurring thesis for WindRose. SubjectWell’s ability to access and match qualified patients to clinical trials through technology and its patient marketplace helps solve a significant pain point in the drug development lifecycle while also increasing access to high-quality care. We are excited to partner with Fred and the SubjectWell team as they continue to execute on their strategy.”
- CJ Burnes, Partner with WindRose
